Intravenous Ascorbic Acid in Women Receiving Adjuvant or Neo-Adjuvant Chemotherapy for Early Stage Breast Cancer

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status score ≤2; * Diagnosed early stage breast cancer and scheduled to receive either adjuvant or neo-adjuvant chemotherapy; * Willing to receive either intravenous ascorbic acid or normal saline; * Willing to use an acceptable contraceptive method for the duration of the study and for 30 days following the last dose of study drug; * Negative urine or serum pregnancy test within 2 weeks prior to receipt of study drug; * Willing to complete all evaluation tools; * Able to give informed consent to participate in the study; and * Agree to avoid any additional supplemental ascorbic acid throughout the study. Exclusion Criteria: * Diagnosed Glucose-6-phosphate dehydrogenase deficiency; * Renal insufficiency (Blood Urea Nitrogen \>30 mg/dL, or Creatinine \>1.5 mg/dL); * Unwillingness or mental incapacity to complete self-reported questionnaires; * Active smoker; and * Male sex